Optum study shows BLC and WLC have equivalent real-world costs for non-muscle-invasive bladder cancer, supporting adoption of blue light cystoscopy without financial penalty
Executive summary: Photocure ASA published an Optum study showing cost neutrality between blue light cystoscopy (BLC) and white light cystoscopy (WLC) in a real-world U.S. setting for non-muscle-invasive bladder cancer. The study removes a major economic objection to BLC adoption by proving superior cancer detection does not raise overall healthcare costs, potentially increasing use of the more accurate diagnostic method.
Who is involved: Photocure ASA (OSE: PHO), Optum, U.S. healthcare providers and payers managing non-muscle-invasive bladder cancer patients.
Likely next: Increased reimbursement discussions, potential updates to clinical guidelines favoring BLC, and expanded market access for Photocure’s Cysview® in the U.S.
Photocure ASA announced the publication of an Optum study demonstrating cost neutrality between blue light cystoscopy (BLC) and white light cystoscopy (WLC) in a real-world U.S. setting for non-muscle-invasive bladder cancer (NMIBC). The retrospective analysis compared healthcare resource utilization and costs, finding no significant difference between the two diagnostic approaches. This evidence addresses a key barrier to BLC adoption — perceived higher costs — by showing that improved detection does not increase overall system expenses.
What's next — scenarios
Standard Market Integration (55%)
BLC transitions from a niche premium tool to a standard-of-care procedure in U.S. urology clinics.
- Increased reimbursement parity in payer policies
- Higher physician adoption rates in Optum-managed networks
Persistent Cost-Perception Barrier (30%)
Slow adoption persists as hospital administrators prioritize immediate procurement costs over long-term system savings.
- New budget impact models from competitors
- Slow uptake of BLC-capable hardware in community hospitals
Accelerated Dominance via Value-Based Care (15%)
BLC adoption accelerates rapidly as payers shift from fee-for-service to outcomes-based reimbursement models.
- Integration of BLC into national clinical guidelines
- Reduction in long-term NMIBC recurrence costs reported in follow-up data
What to watch
- Payer coverage updates for BLC procedures (next 60 days)
- Photocure ASA quarterly sales volume updates (next 90 days)
- Urology specialty society clinical guideline reviews (next 90 days)
Timeline
- — Cost neutrality of BLC versus WLC in a real-world setting demonstrated by new OPTUM study in the U.S. (PR Newswire)
Analysis — what this means
Likely next events
- Photocure to present findings at AUA 2027
- Optum to consider BLC in value-based care models by Q1 2027
- CMS to review BLC coverage policies by mid-2027
Sectors affected
- Medical diagnostics
- Urology healthcare services
- Bladder cancer drug and device market
Regulatory implications
- CMS could update HCPCS coding or payment rules for BLC procedures based on cost equivalence
- NCCN guidelines may strengthen BLC recommendation based on cost-neutral efficacy
Historical parallels
- Adoption of HPV testing vs. Pap smear in cervical cancer screening (2010s) — showed cost-effectiveness despite higher upfront cost
- MRI-guided biopsy vs. TRUS in prostate cancer diagnosis (2018–2020) — demonstrated long-term savings via reduced overdiagnosis
Key entities
Sources
- Cost neutrality of BLC versus WLC in a real-world setting demonstrated by new OPTUM study in the U.S. — PR Newswire